Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH
5 search results for:

Marc D Cohen 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 22-03-2018 | Biosimilars | Editorial | Article

    Biosimilars: The price is not right

    Marc Cohen analyzes the various economic factors influencing the price of biosimilars over recent years in rheumatology, focusing on the United States healthcare system.

    Author:
    Marc D. Cohen
  2. 24-10-2017 | Rheumatoid arthritis | Editorial | Article

    Demise of the triple

    Marc Cohen reviews the use of triple therapy for the treatment of rheumatoid arthritis, and discusses the possible reasons for its underutilization compared with biologic therapies.

    Author:
    Marc D. Cohen
  3. 17-10-2019 | Teaser
    ACR/ARP 2019 clinical trial recommendation

    Efficacy and Safety of Fenebrutinib, a BTK Inhibitor, Compared to Placebo in Rheumatoid Arthritis Patients with Active Disease Despite TNF Inhibitor Treatment: Randomized, Double Blind, Phase 2 Study

    Sunday,   November 10, 17:00–17:15. Georgia World Congress Center, Atlanta, USA Presenting author:  Stanley B Cohen, USA What our Editorial Board said: This is the first phase II trial of a Bruton’s tyrosine kinase (BTK) inhibitor in patients with rheumatoid arthritis (RA) identified as a population with existing unmet medical need.  This reasonably sized trial should provide useful information regarding whether or not this anticipated class of biologics demonstrates significant clinical efficacy in a challenging subset of previously treated patients with RA. –  Marc D Cohen, USA

  4. 17-10-2019 | Teaser
    ACR/ARP 2019 clinical trial recommendation

    Monotherapy with Upadacitinib in MTX-naïve Patients with Rheumatoid Arthritis: Results at 48 Weeks

    Sunday,   November 10, 16:45–17:00. Georgia World Congress Center, Atlanta, USA Presenting author:  Ronald van Vollenhoven, Netherlands What our Editorial Board said: The SELECT-EARLY trial should provide more information regarding whether or not the JAK1 selective inhibitor upadacitinib continues to compare favorably with methotrexate as monotherapy in patients with early rheumatoid arthritis (RA).  If the results are impressive, and there are no new safety signals, there will be even more intense discussion of the best choice for initial therapy in RA. –  Marc D Cohen, USA

  5. 09-05-2018 | Vasculitis | Case report | Article

    The first case of bacillus Calmette-Guérin-induced small-vessel central nervous system vasculitis

    Babjuk M, Bohle A, Burger M, Capoun O, Cohen D, Comperat EM et al (2016) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016.

  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.